Trial Profile
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2014
Price :
$35
*
At a glance
- Drugs RU 105 (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 09 May 2014 New trial record